IRIS
PARENTI, Carmela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.409
EU - Europa 2.809
AS - Asia 1.851
AF - Africa 410
SA - Sud America 300
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 5
Totale 11.795
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.199
SG - Singapore 970
IT - Italia 961
CN - Cina 694
IE - Irlanda 614
UA - Ucraina 531
CI - Costa d'Avorio 283
BR - Brasile 276
CA - Canada 200
RU - Federazione Russa 178
DE - Germania 175
SN - Senegal 103
SE - Svezia 96
GB - Regno Unito 44
FR - Francia 42
IN - India 41
JP - Giappone 40
BE - Belgio 25
VN - Vietnam 25
NL - Olanda 20
ES - Italia 18
CH - Svizzera 17
FI - Finlandia 17
UZ - Uzbekistan 17
AT - Austria 15
CZ - Repubblica Ceca 11
PL - Polonia 11
AU - Australia 10
GR - Grecia 10
MX - Messico 8
AR - Argentina 7
HU - Ungheria 7
IR - Iran 7
TR - Turchia 7
AE - Emirati Arabi Uniti 6
CO - Colombia 6
LB - Libano 6
PK - Pakistan 6
EU - Europa 5
MA - Marocco 5
TH - Thailandia 5
HK - Hong Kong 4
IL - Israele 4
IQ - Iraq 4
NG - Nigeria 4
NO - Norvegia 4
ZA - Sudafrica 4
AZ - Azerbaigian 3
BD - Bangladesh 3
BG - Bulgaria 3
DZ - Algeria 3
ID - Indonesia 3
PE - Perù 3
TN - Tunisia 3
AL - Albania 2
CL - Cile 2
DK - Danimarca 2
EC - Ecuador 2
EG - Egitto 2
KE - Kenya 2
VE - Venezuela 2
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
HR - Croazia 1
KZ - Kazakistan 1
LI - Liechtenstein 1
LK - Sri Lanka 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SL - Sierra Leone 1
SV - El Salvador 1
UY - Uruguay 1
Totale 11.795
Salva come PNG Salva come JPEG
Città #
Houston 1.018
Santa Clara 990
Chandler 794
Dublin 610
Singapore 547
Jacksonville 512
Chicago 459
Catania 301
Boardman 289
Abidjan 283
Ashburn 214
Nanjing 190
Cambridge 173
Lawrence 173
Andover 171
Toronto 154
Dakar 103
Civitanova Marche 94
Wilmington 94
San Mateo 87
Bremen 83
Des Moines 71
Nanchang 65
Council Bluffs 62
Shenyang 52
Saint Petersburg 46
Jiaxing 42
Ottawa 42
Rome 42
Changsha 40
Tianjin 38
Hebei 34
Tokyo 33
Grafing 32
Munich 30
Naples 30
Beijing 27
Brussels 24
Los Angeles 24
São Paulo 22
Moscow 18
Dong Ket 17
Falls Church 17
Pune 17
Jinan 15
Ningbo 15
Norwalk 15
Seattle 15
San Giovanni la Punta 14
Augusta 13
Helsinki 13
Messina 13
Washington 13
Mascalucia 11
Zhengzhou 11
Belo Horizonte 10
Paternò 10
Kunming 9
Leawood 9
Madrid 9
New York 9
Rio de Janeiro 9
Salerno 9
Ann Arbor 8
Fremont 8
Fuzhou 8
Liberty Lake 8
Tappahannock 8
Brno 7
Budapest 7
East Stroudsburg 7
Palermo 7
Salvador 7
Siracusa 7
The Dalles 7
Ardabil 6
Bologna 6
Cagliari 6
Campinas 6
Den Haag 6
Fukuoka 6
Groningen 6
Marseille 6
Melbourne 6
Mountain View 6
Redwood City 6
San Gregorio di Catania 6
Tashkent 6
Amsterdam 5
Centro 5
Dearborn 5
Froges 5
Hanoi 5
Heidelberg 5
Lentini 5
Milan 5
Misterbianco 5
Monmouth Junction 5
Pace 5
Recife 5
Totale 8.613
Salva come PNG Salva come JPEG
Nome #
Wilms' tumor gene 1 silencing inhibits proliferation of human osteosarcoma MG-63 cell line by cell cycle arrest and apoptosis activation. 419
Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation 375
NOP RECEPTOR ANTAGONISM IN THE VENTROLATERAL PERIAQUEDUCTAL GRAY ATTENUATES THE DEVELOPMENT OF OPIOID TOLERANCE. 296
((2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist 207
Involvement of sigma 2 receptor on motor disorder 164
Neuroprotective effects of Rosmarinus officinalis L. extract in oxygen glucose deprivation (OGD)-injured human neural-like cells 136
Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands 120
Influenza del N-sostituente della (–)-cis-N-Normetazocina nella modulazione del profilo funzionale al MOR, DOR e KOR: da agonista ad antagonista attraverso ligandi misti agonisti/antagonisti 118
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist 107
Inhibition of Cx43 mediates protective effects on hypoxic/reoxygenated human neuroblastoma cells 106
Development of a Sigma-2 Receptor affinity filter through a Monte Carlo based QSAR analysis 99
Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists 96
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists 95
From plant to bench: natural products as source for analgesic drug development. 93
Studio aerobiologico e incidenza di pollinosi nella popolazione acese 91
(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects 91
Sigma-2 receptor ligands QSAR model dataset 89
R- ed S-LP2: sintesi, molecular docking e valutazione farmacologica 89
Intercellular communication and ion channels in neuropathic pain chronicization 89
CHF5074 protects SH-SY5Y human neuronal-like cells from amyloidbeta 25-35 and tumor necrosis factor related apoptosis inducing ligand toxicity in vitro 87
LP2 e 2S-LP2: agonisti biased dual target MOR/DOR nel trattamento del dolore cronico 86
Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands 85
Lipid Nanoparticle Inclusion Prevents Capsaicin-Induced TRPV1 Defunctionalization 85
Development of novel LP1-based analogues with enhanced delta opioid receptor profile 84
Connexins in the central nervous system: physiological traits and neuroprotective targets 84
In Vitro Antioxidant Activity and In Vivo Topical Efficacy of Lipid Nanoparticles Co-Loading Idebenone and Tocopheryl Acetate 84
The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-β1 Signalling 83
Chronic treatment with fluoxetine induces sex-dependent analgesic effects and modulates HDAC2 and mGlu2 expression in female mice 81
Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review 81
The benzomorphan-based compound LP1 is a central acting MOR agonist/DOR antagonist suitable for chronic pain treatment 80
The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment 78
Wilms’ Tumor Gene 1 (WT1) silencing inhibits proliferation of malignant peripheral nerve sheath tumor sNF96.2 cell line 78
Effect of CCK-8 on analgesia induced by cold-restraint stress in the rat 77
Central and peripheral control by endogenous opioid peptides of gastric protection in stressed-rats 77
The antagonistic effect of the sigma 1 receptor ligand (+)-MR200 on persistent pain induced by inflammation. 76
ANTIALLODINIC AND ANTIHYPERALGESIC EFFECTS OF LP1, AN OPIOID MULTITARGET LIGAND, IN INFLAMMATORY AND NEUROPATHIC PAIN STATES 76
Ischemic tolerance modulates TRAIL expression and its receptors and generates a neuroprotected phenotype 75
Prevention of stress-induced gastric ulcers by mu- and delta-opioid agonists in the rat. 74
Dual MOR/DOR agonist benzomorphan-based compounds for pain relief 74
Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand. 74
Novel Sigma-1 receptor antagonists: From opioids to small molecules: What is new? 74
A new Sigma-1 Receptor antagonist in Chronic Pain Treatment: (+)-2R/S-LP2 effects in inflammatory and neuropathic pain 72
Multitarget opioid ligands in pain relief: New players in an old game 72
Wilms' tumor 1 (WT1) protein expression in human developing tissues 71
A new sigma ligand, (+/-)-PPCC, antagonizes kappa opioid receptor-mediated antinociceptive effect 71
Tumor necrosis factor-related apoptosis-inducing ligand reduces the expression of the neuroprotective Na+ /Ca2+ exchanger isoform NCX3 in human neuroblastoma SH-SY5Y cells 71
Effects of dinorphin 1-13 on hyperalgesia induced by interleukin-1bera in the rat 70
Neuroprotective effect of the new sigma receptor ligands cis-(+) and cis-(–)-PPCC 70
Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management 70
Repeated activation of delta opiod receptors counteracts nerve injury-induced TNF-α up-regulation in the sciatic nerve of rats with neuropathic pain: A possible correlation with delta opiod receptors-mediated antiallodinic effect. 70
Evaluation of N-substituent structural variations in opioid receptor profile of LP1. 70
Simultaneous Activation of Mu and Delta Opioid Receptors Reduces Allodynia and Astrocytic Connexin 43 in an Animal Model of Neuropathic Pain 70
Involvement of the Heme-Oxygenase Pathway in the Antiallodynic and Antihyperalgesic Activity of Harpagophytum procumbens in Rats. 69
Mu and Delta Opioid Receptor Targeting Reduces Connexin 43-Based Heterocellular Coupling during Neuropathic Pain 68
Effect of supraspinal Nocistatin on nociceptin/OrphaninFQ antagonism of selective opioid analgesia 68
Activity of profens as racemic (R and S) enantiomers in human condrocytes and cartilage 68
The Benzomorphan-Based Compound LP1 as Suitable Candidate for Pain Management 68
Benzomorphan scaffold for opioid analgesics and pharmacological tools development: A comprehensive review 68
Preclinical evidence of enhanced analgesic activity of duloxetine complexed with succinyl-β-cyclodextrin: A comparative study with cyclodextrin complexes 68
Progress in the development of more effective and safer analgesics for pain management 67
In vitro and in vivo pharmacological evaluation of LP1, a benzomorphan-based compound 66
Activity of profens as racemic (R and S) enantiomers in human condrocytes and cartilage 66
MOR/DOR targeting: an useful strategy in pain management 66
Role of the Nrf2/HO-1 axis in bronchopulmonary dysplasia and hyperoxic lung injuries 66
THE BENZOMORPHAN-BASED COMPOUND LP1 AS A MULTITARGET OPIOID LIGAND FOR CHRONIC PAIN TREATMENT 65
Apoptotic effects of (±) MRJF4 in prostate cancer cells 65
Rosemary Essential Oil-Loaded Lipid Nanoparticles: In Vivo Topical Activity from Gel Vehicles 65
Effects of a Selective Sigma 1 Antagonist Compound on Inflammatory Pain 65
The blockade of NOP receptor in the vlPAG reduces the development of tolerance to opioid-induced antinociception in rats 64
Scouting new sigma receptor ligands: Synthesis, pharmacological evaluation and molecular modeling of 1,3-dioxolane-based structures and derivatives 64
Rescue of noradrenergic system as a novel pharmacological strategy in the treatment of chronic pain: Focus on microglia activation 64
Involvement of the Nociceptin/Orphanin FQ-NOP receptor system in the ventrolateral periaqueductal gray following mechanical allodynia in chronic pain 63
(+)-Mr200 derivatives: modifications on the amino moiety. In vitro and in vivo pharmacological evaluation 63
Blockade of the nociceptin/orphanin FQ/NOP receptor system in the rat ventrolateral periaqueductal gray potentiates DAMGO analgesia 62
Design, synthesis, and biological evaluation of new hybrid MOR agonist/HDACi compounds: an innovative approach for persistent pain management 61
Stress-induced changes in the thermic effects of cholecystokinin in the rat 61
Harpagophytum procumbens extract potentiates morphine antinociception in neuropathic rats. 61
Antiallodynic and antihyperalgesic effects of intraplantar nocistatin and (+/-)-J113397 in inflammatory pain 60
INVOLVEMENT OF ENDOGENOUS OPIOIDS IN THE ANALGESIC EFFECT OF SUBSTANCE P AT SUPRASPINAL LEVEL 60
An LP1 analogue, selective MOR agonist with a peculiar pharmacological profile, used to scrutiny the ligand binding domain 60
In-vitro evaluation of a new benzomorphan-based ligand 60
Synthesis and in vitro opioid receptor studies on benzomorphan-based compounds: LP1, a potent and long-acting antinociceptive 60
Prevention of stress-induced gastric ulcers by m- and d-opioid agonists in the rat 59
Involvement of prostaglandins on morphine-induced gastric protection in rats 59
Opioid and sigma receptor studies. New developments in the design of selective sigma ligands 59
The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures 59
HDAC and HAT inhibitors differently affect analgesia mediated by group II metabotropic glutamate receptors 58
ANTIALLODYNIC AND ANTIHYPERALGESIC EFFECTS OF INTRAPLANTAR NOCISTATIN AND (±)-J 113397 IN INFLAMMATORY PAIN 58
Sigma-1 Receptor Inhibition Reduces Mechanical Allodynia and Modulate Neuroinflammation in Chronic Neuropathic Pain 57
Inhibition of pain response in the formalin test by naloxone in normal- or cold-.restrained-rats 57
A New LP1 analogue is used to better understand MOR ligand Binding Domain and its mechanisms of activation 57
Different in vitro activity of flurbiprofen and its enantimers on human articular cartilage 57
effetti dell'orfaninaFQ sull'analgesia da oppioidi nel ratto 56
New bifunctional antioxidant/σ1 agonist ligands: preliminary chemico-physical and biological evaluation 56
In vitro evaluation of new benzomorphan-based ligands 56
Pain management: new long-acting opioid ligands 56
Synthesis and structure-activity relationships of (–)-cis-N-normetazocine-based LP1 derivatives 56
The molecular mechanism of central analgesia induced by mu- or delta-opioid agonist and the l-arginine-NO-cGMP pathway 55
FARMACODINAMICA DEGLI ENANTIOMERI (S),(R),DEL FLURBIPROFENE E KETOPROFENE IN COLTURE DI CARTILAGINE UMANA E CONDROCITI 55
Antiallodinic and antihyperalgesic effects of LP1, an opioid multitarget ligand, in inflammatory and neurophatic pain states 55
Totale 8.366
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.193
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.193
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020164 0 0 0 0 0 0 0 0 0 0 113 51
2020/20211.069 15 92 116 34 294 35 106 8 110 16 170 73
2021/20221.382 163 178 15 38 210 16 186 56 123 23 56 318
2022/20232.419 196 127 46 291 214 378 8 439 512 45 101 62
2023/20241.265 82 218 78 62 68 286 48 76 2 33 218 94
2024/20253.575 67 747 214 236 877 480 196 188 247 322 1 0
Totale 12.231